NASDAQ · OCSAW
Oculis Holding AG Warrants financials
$2.74−1.76%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '25 Dec 31 | Q4 '24 Dec 31 | Q4 '23 Dec 31 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Gross margin | — | — | — |
| Operating income | — | — | — |
| Net income | — | — | — |
| Net margin | — | — | — |
| Diluted EPS | — | — | — |
| EBITDA | $0.00 | $0.00 | $0.00 |
| Operating cash flow | — | — | — |
| Free cash flow | — | — | — |
| Diluted shares | 52.2M | 40.4M | 29.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $102.5M | $30.7M | $45.6M |
| Short-term investments | $165.9M | $78.6M | $63.4M |
| Total debt | $0.00 | $0.00 | $449.5K |
| Total assets | $297.3M | $133.2M | $136.0M |
| Total liabilities | $50.3M | $52.0M | $24.5M |
| Shareholders' equity | $247.1M | $81.2M | $111.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology